353 related articles for article (PubMed ID: 16207072)
21. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma.
Witzig TE
Semin Oncol; 2003 Dec; 30(6 Suppl 17):11-6. PubMed ID: 14710398
[TBL] [Abstract][Full Text] [Related]
23. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.
Schnell R; Dietlein M; Schomäcker K; Kobe C; Borchmann P; Schicha H; Hallek M; Engert A
Onkologie; 2008 Feb; 31(1-2):49-51. PubMed ID: 18268399
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Borghaei H; Schilder RJ
Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):4-9. PubMed ID: 14762738
[TBL] [Abstract][Full Text] [Related]
25. Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin).
Gregory SA
Semin Oncol; 2003 Dec; 30(6 Suppl 17):17-22. PubMed ID: 14710399
[TBL] [Abstract][Full Text] [Related]
26. Ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Johnston PB; Bondly C; Micallef IN
Expert Rev Anticancer Ther; 2006 Jun; 6(6):861-9. PubMed ID: 16761929
[TBL] [Abstract][Full Text] [Related]
27. Radioimmunotherapy for B-cell non-hodgkin lymphomas.
Tomblyn M
Cancer Control; 2012 Jul; 19(3):196-203. PubMed ID: 22710895
[TBL] [Abstract][Full Text] [Related]
28. Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma.
Hagenbeek A; Lewington V
Ann Oncol; 2005 May; 16(5):786-92. PubMed ID: 15802280
[TBL] [Abstract][Full Text] [Related]
29. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
Wiseman GA; White CA; Stabin M; Dunn WL; Erwin W; Dahlbom M; Raubitschek A; Karvelis K; Schultheiss T; Witzig TE; Belanger R; Spies S; Silverman DH; Berlfein JR; Ding E; Grillo-López AJ
Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488
[TBL] [Abstract][Full Text] [Related]
30. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.
Grillo-López AJ
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S44-9. PubMed ID: 15786025
[TBL] [Abstract][Full Text] [Related]
31. Logistics of therapy with the ibritumomab tiuxetan regimen.
Meredith RF
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S35-8. PubMed ID: 16979437
[TBL] [Abstract][Full Text] [Related]
32. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
[TBL] [Abstract][Full Text] [Related]
33. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
[TBL] [Abstract][Full Text] [Related]
34. Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Gordon LI
Semin Oncol; 2003 Dec; 30(6 Suppl 17):23-8. PubMed ID: 14710400
[TBL] [Abstract][Full Text] [Related]
35. 90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr.
Mondello P; Cuzzocrea S; Navarra M; Mian M
Oncotarget; 2016 Feb; 7(7):7597-609. PubMed ID: 26657116
[TBL] [Abstract][Full Text] [Related]
36. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
Wiseman GA; Witzig TE
Cancer Biother Radiopharm; 2005 Apr; 20(2):185-8. PubMed ID: 15869453
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy.
Justice TE; Martenson JA; Wiseman GA; Witzig TE
Cancer; 2006 Jul; 107(2):433-8. PubMed ID: 16770786
[TBL] [Abstract][Full Text] [Related]
38. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy.
Jacobs SA; Vidnovic N; Joyce J; McCook B; Torok F; Avril N
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7146s-7150s. PubMed ID: 16203814
[TBL] [Abstract][Full Text] [Related]
39. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
Schilder R; Molina A; Bartlett N; Witzig T; Gordon L; Murray J; Spies S; Wang H; Wiseman G; White C
Cancer Biother Radiopharm; 2004 Aug; 19(4):478-81. PubMed ID: 15453962
[TBL] [Abstract][Full Text] [Related]
40. Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin): the role of the nuclear medicine physician.
Conti PS
Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):2-3. PubMed ID: 14762737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
